No author has a financial or proprietary interest in any material or method mentioned.

Purpose: To assess the efficacy of topical 1.5% azithromycin in the treatment of mo derate to severe chronic blepharitis and to compare the efficacy of two different treatment modalities. Methods: A randomized clinical trial included 67 patients with chronic anterior and/or posterior blepharitis, followedup for 3 months. Signs and symptoms were graded according to severity. Patients were randomized into two groups: 33 patients in group I and 34 patients in group II. Group I patients were treated with topical 1.5% azithromycin twice a day for three days, and Group II patients were treated with topical 1.5% azithromycin twice a day for three days then at bedtime for the rest of the month. All patients were instructed to apply warm compresses and an eyefriendly soap twice daily. Results: Patients in both groups tolerated the treatment with minimal irritation. A signi ficant improvement in signs and symptoms was noted at the one week fol lowup visit. Group II showed a more pronounced and longerlasting improvement that persisted after three months of followup. Conclusion: Topical 1.5% azithromycin ophthalmic solution is an effective treat ment option for chronic blepharitis. In moderate to severe blepharitis, a one month treatment is safe and shows better improvement than the threeday protocol with no significant relapse until three months of followup.

Implantation of Intacs SK for moderate to severe keratoconus is safe and effective, leading to significant decrease in myopia and appreciable decrease in astigmatism with improvement in CDVA.

No author has a financial or proprietary interest in any material or method mentioned.